Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT00293761
First received: February 17, 2006
Last updated: March 2, 2012
Last verified: March 2012

February 17, 2006
March 2, 2012
January 2006
May 2006   (final data collection date for primary outcome measure)
Mean IOP
Not Provided
Complete list of historical versions of study NCT00293761 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
Not Provided

The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Open-angle Glaucoma
  • Ocular Hypertension
  • Drug: Travoprost, Investigational
    One drop in study eye once daily for 13 days
  • Drug: Travoprost (TRAVATAN)
    One drop in study eye once daily for 13 days
    Other Name: TRAVATAN
  • Experimental: Travatan, Investigational
    Intervention: Drug: Travoprost, Investigational
  • Active Comparator: Travatan
    Intervention: Drug: Travoprost (TRAVATAN)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
109
May 2006
May 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients of either sex of any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Under age 18.
  • Other protocol-defined exclusion criteria may apply.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00293761
C-05-51
Not Provided
Alcon Research
Alcon Research
Not Provided
Not Provided
Alcon Research
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP